Swiss pharmaceutical giant Novartis NVS announces a series of multibillion-dollar deals Tuesday.
Gilead Sciences (GILD) has an estimated total return of 45.4% according to a research note published by Citigroup.
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
The recent large intra-week swings are having investors scratching their heads.
Does a recreational drug and horse tranquilizer really have potential as an effective treatment for one of the toughest, and most common, psychiatric illnesses out there?
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
St. Jude Medical (STJ) tumbles in trading despite beating analysts EPS estimates by 1 cent
Abbot Laboratories (ABT) earnings report beats EPS estimates but falls short on revenue
Regeneron Pharmaceuticals (REGN) had coverage initiated on its shares with a 'buy' rating by analysts at Canaccord Genuity
Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
The recent sluggish performance of U.S. stocks is leading some market watchers to question whether we're witnessing the bursting of an equity bubble.
Investors say Johnson & Johnson's earnings beat will take the Dow and the biotech sector higher today.
CSX Corp and Abbott Labs complete the four companies that report after the close today or before the opening bell on Wednesday.
Prepare yourself for more downside even if we do bounce this week.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV